Is CVM a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,763 people get CVM articles and Market Currents by email alert.

Get email alerts on CVM »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Cel-Sci: Immunotherapy Opens New Door To Investors
James Stocklasar Thomas Jr. • Thu, Dec 6, 2012 • 13 Comments
Cel-Sci's Successful Safety Review Not Yet Factored Into Valuation
Ray Dirks • Fri, Nov 2, 2012 • 12 Comments
Cel-Sci Shares Still Undervalued: How Does This Make Sense?
Ray Dirks • Thu, Apr 19, 2012 • 9 Comments
Technical And Fundamental Breakout In Play For CEL-SCI Corporation
Michael Morhamus • Wed, Mar 21, 2012 • 5 Comments
Cel-Sci Offers Huge Potential Gains With Revolutionary Immunotherapy Anti-Cancer Drug
Brian L. Wilson • Tue, Mar 13, 2012 • 18 Comments
All Eyes on Cel-Sci: Will Wednesday's Surge Continue?
VFC's Stock House • Thu, Dec 10, 2009 • 22 Comments
Holiday Cheer: Cel-Sci Should Have Good News
VFC's Stock House • Wed, Nov 25, 2009 • 33 Comments
Cel-Sci: Good News Could Lead to Long-Term Growth
VFC's Stock House • Tue, Nov 10, 2009 • 14 Comments
Cel-Sci, Johns Hopkins Move Forward with LEAPS
VFC's Stock House • Sun, Nov 8, 2009 • 9 Comments
Cel-Sci's Targets Stay on Track
VFC's Stock House • Tue, Oct 27, 2009 • 20 Comments
Cel-Sci: Things Are Just Getting Started
VFC's Stock House • Tue, Oct 20, 2009 • 15 Comments
Cel-Sci: Why I'm Buying if the Price Dips
VFC's Stock House • Wed, Oct 14, 2009 • 13 Comments
Cel Sci: Job Listings Are a Good Sign
VFC's Stock House • Thu, Oct 8, 2009 • 9 Comments
Remaining Grounded Through the Unethical Attacks on Cel Sci
VFC's Stock House • Thu, Oct 8, 2009 • 31 Comments
Investors Should Ignore the Hoopla Around Cel Sci
VFC's Stock House • Wed, Oct 7, 2009 • 20 Comments
Cel-Sci May Be in for a Bumpy Ride This Week
VFC's Stock House • Mon, Oct 5, 2009 • 34 Comments
Cloak and Dagger Developments at Cel-Sci Against Swine Flu
M. E. Garza • Thu, Sep 17, 2009 • 16 Comments
Cel-Sci Thrives with New Manufacturing Facility
M. E. Garza • Tue, Aug 25, 2009 • 9 Comments
CEL-SCI CEO's Bullish Biotech Play
M. E. Garza • Sun, Aug 23, 2009 • 5 Comments
Not Buying Cel Sci's Swine Flu PR
VFC's Stock House • Tue, Aug 18, 2009 • 11 Comments

To learn more about Seeking Alpha Pro, click here.

Three Biotech Stocks With Low Price But Great Potential
Craig Keolanui • Tue, Apr 16 • 8 Comments
Buying Teva's Immunotherapy Investment
James Stocklasar Thomas Jr. • Wed, Dec 5, 2012 • 9 Comments
4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce
MarketScanners • Tue, Nov 20, 2012 • 11 Comments
Risk Vs. Reward Never Gets Old
Shlomo Wiesen • Tue, Oct 23, 2012 • 15 Comments
3 High Beta Liquid Small-Cap Biotechnology Stocks That Are Breaking Out
R.S. Analytics • Mon, Sep 17, 2012 • 3 Comments
Astex's Linear Rise Versus Peregrine's And Cell Therapeutics' Sudden Pop
James Stocklasar Thomas Jr. • Mon, Sep 10, 2012 • 15 Comments
Weekly Stock Watch: Week Of August 13
VFC's Stock House • Mon, Aug 13, 2012 • 2 Comments
Weekly Stock Watch: Week Of June 25
VFC's Stock House • Mon, Jun 25, 2012 • 7 Comments
Why Novartis Leads The Way In Oncology Research
James Stocklasar Thomas Jr. • Fri, Jun 22, 2012 • 15 Comments
Earnings Preview: Pluristem Therapeutics
Vytautas Drumelis • Tue, Jun 19, 2012
Orphan Drug Designation Biotechs For Investment Consideration
Chemistfrog • Tue, Jun 12, 2012 • 11 Comments
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy
ZetaKap • Fri, May 25, 2012
Darling Dendreon Takes Hits As Speculators Continue To Bet On Immunotherapy Plays
M. E. Garza • Wed, May 23, 2012 • 25 Comments
Weekly Stock Watch: May 21-25
VFC's Stock House • Mon, May 21, 2012 • 2 Comments
Update On 26 Stocks For the Week Of May 14
VFC's Stock House • Sun, May 13, 2012 • 2 Comments
3 Rising Biotech Stocks To Keep A Close Eye On For Trading Profits
E. Michael Greenberg • Thu, May 10, 2012 • 7 Comments
Cel-Sci Corp, Synergy Pharmaceuticals Stocks Rise: Investors Should Start Paying Attention
VFC's Stock House • Tue, May 1, 2012 • 4 Comments
Weekly Stock Watch: April 30-May 4
VFC's Stock House • Sun, Apr 29, 2012 • 3 Comments
Weekly Stock Watch: April 9-13
VFC's Stock House • Mon, Apr 9, 2012
Weekly Stock Watch: April 2-6
VFC's Stock House • Sun, Apr 1, 2012 • 6 Comments

There are no Transcripts on CVM.

CEL-SCI Corporation Reports Second Quarter 2013 Financial Results

Business Wire (May 10, 2013)
CEL-SCI Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal Model

Business Wire (May 6, 2013)
CEL-SCI To Present at the American Association of Immunologists 100th Annual Meeting on Saturday May 4th

Business Wire (May 3, 2013)
CEL-SCI Corporation Provides Update on Phase III Clinical Trial

Business Wire (Apr 23, 2013)
CEL-SCI Corporation Announces That NIAID Collaborators Have Submitted Bird Flu Study for Publication to Prestigious Scientific Journal

Business Wire (Apr 8, 2013)
CEL-SCI Corporation Releases New Video on Its Website

Business Wire (Apr 2, 2013)
Taglich Brothers Initiates Coverage on CEL-SCI Corporation

Marketwire (Mar 4, 2013)
CEL-SCI Announces Initiation of New Sites for Multikine Phase III Clinical Study for Head and Neck Cancer in Taiwan

Business Wire (Feb 25, 2013)
CEL-SCI Corporation Reports First Quarter 2013 Financial Results

Business Wire (Feb 8, 2013)
CEL-SCI to Present at 15th Annual BIO CEO & Investor Conference

Business Wire (Feb 7, 2013)
CEL-SCI and Northeast Ohio Medical University Develop Novel Cancer Vaccine That Prevents and Treats Breast Cancer

Business Wire (Jan 31, 2013)
CEL-SCI Corporation Announces Fiscal 2012 Financial Results

Business Wire (Dec 14, 2012)
CEL-SCI Corporation to Raise $10.5 Million in Registered Direct Offering

Business Wire (Dec 4, 2012)
CEL-SCI Corporation Releases Letter to Shareholders

Business Wire (Nov 30, 2012)
CEL-SCI Receives Key Japanese Patent for Its Investigational Phase III Cancer Therapy Multikine

Business Wire (Nov 28, 2012)
CEL-SCI Corporation Announces Results of Interim Review of Data from Its Ongoing Phase III Head and Neck Cancer Trial by Independent Data Monitoring Committee (IDMC)

Business Wire (Oct 22, 2012)
CEL-SCI Corporation Reports Third Quarter 2012 Financial Results

Business Wire (Aug 9, 2012)
CEL-SCI Corporation to Raise $5.60 Million in Registered Direct Offering

Business Wire (Jun 19, 2012)
CEL-SCI Corporation Releases Letter to Shareholders

Business Wire (May 18, 2012)
CEL-SCI’s Chief Scientific Officer Presents at Cancer Symposium

Business Wire (May 15, 2012)

CVM vs. ETF Alternatives

Company Description

CEL-SCI's business consists of the following:

1) Multikine(R) cancer therapy;
2) New "cold fill" manufacturing service to the pharmaceutical industry;
and
3) LEAPS technology, with two products, H1N1 swine flu treatment for
H1N1 hospitalized patients and CEL-2000, a rheumatoid... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 8, 2:14 PM CEL-SCI Corporation (CVM -2.5%) isn't getting much of a lift today, despite its announcement that collaborators at the National Institute of Allergy and Infectious Diseases have submitted for publication the results from efficacy studies in animals using CVM's H1N1 activated dendritic cells to treat the H1N1 bird flu virus. This work may possibly also be applicable to the new H7N9 bird flu strain currently detected in China, but no definitive statement has yet been made to that effect. Comment! [Healthcare, On the Move, Global & FX]
Friday, February 8, 4:39 PM CEL-SCI (CVM) reports a Q1 loss of $0.02, in-line with estimates and even with a loss of $0.02 reported for Q1 2012. Net losses were $2.3M versus losses of $4.2M during the prior year period. R&D expenses increased by 25% Y/Y, largely due to the increased level of activity associated with conducting Phase III clinical studies. Shares -0.5% AH. 1 Comment [Healthcare, Earnings, Breaking News]
Thursday, January 31, 12:47 PM CEL-SCI (CVM +2.3%) gains after announcing that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease. In addtion to finding an absence of tumors in lymph nodes or peritoneal membranes, the vaccine also demonstrated a reduction in the number of tumors and tumor mass. Comment! [Healthcare, On the Move]
Friday, November 30, 2012, 3:10 PM Cel-Sci (CVM +3.5%) has rallied after issuing a shareholder letter in which the company expressed confidence about the outlook for Phase III trials of its Multikine immunotherapy treatment for head and neck cancer. The company also said it plans to increase the number of patient recruitment centers for the trials to at least 50, comapred with a current 36. 3 Comments [Healthcare, On the Move]
Wednesday, June 27, 2012, 10:44 AM Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for head and neck cancer is performing well in Phase 3 trials. "Based on everything that we've seen in the clinic so far, if we continue to see the same results, we will have the first non-toxic cancer therapy," Kersten tells eHealth Radio. Comment! [Healthcare, On the Move]
Wednesday, March 21, 2012, 9:14 AM Premarket gainers: ASGN +25%. FSII +15%. USG +13%. YPF +9%. HIG +7%. LNKD +6%. CVM +6%. LXRX +5%. LGF +3%.
Losers: AGO -10%. BHI -4%. ZLCS -3%. STP -3%. PHG -3%. Comment! [On the Move]
Tuesday, February 7, 2012, 9:00 AM Premarket gainers: CSTR +19%. CVM +11%. SPF +10%. SHPGY +5%. S +5%. AMLN +4%. NBG +4%. PRGO +3%. HGSI +3%. CLF +3%. CHU +3%.
Losers: NSU -22%. CFX -10%. ASTX -10%. BPAX -6%. LPL -5%. THLD -5%. SBH -4%. ALU -4%. ZOLT -4%. FRO -3%. VHPM -3%. CTIC -3%. Comment! [On the Move]
Monday, January 23, 2012, 1:09 PM Cel-Sci Corporation (CVM +8%) pops after saying late Friday that phase III clinical trials for its cancer drug Multikine were launched in dozens of hospitals located in eight countries on three continents. Comment! [Healthcare, On the Move]
Monday, January 23, 2012, 9:00 AM Premarket gainers: MFN +29%. CVM +10%. BVSN +9%. CHK +7%. FRO +5%. SWN +5%. CGO +3%. NBG +3%. FST +3%. DANG +3%. LYG +3%.
Losers: FSC -4%. RIMM -4%. NFLX -3%. SIRI -3%. Comment! [On the Move]
Wednesday, January 18, 2012, 9:10 AM Premarket gainers: UEPS +31%. CVM +16%. CBRX +16%. KUTV +11%. LLTC +8%. ZLTQ +7%. NBG +7%. WFR +5%. ING +4%. FRO +4%. HEK +3%. STM +3%. YHOO +3%. OMX +3%.
Losers: PSLV -10%. RIMM -6%. PCX -5%. CREE -4%. FAST -4%. BK -3%. BGLS -3%. GEN -3%. Comment! [On the Move]
Tuesday, December 27, 2011, 12:13 PM Microcap biotech Cel-Sci (CVM +0.3%) says it's expanding the Phase III clinical trials of its Multikine investigational injection therapy to four additional European countries, including Spain, the Czech Republic, Slovakia and Croatia. Comment! [Healthcare]
Monday, December 13, 2010, 9:10 AM Premarket gainers: DNEX +20%. NSTC +20%. VLNC +9%. PZG +7%. PCBC +7%. LOCM +6%. XRA +5%. APWR +5%. HL +5%. JDSU +5%. PTIE +4%. CCME +5%. CVM +4%. IRE +4%. CHU +4%.
Losers: NKTR -11%. OCZ -7%. ZSL -6%. HBAN -4%. Comment!
Tuesday, April 13, 2010, 9:00 AM Premarket gainers: MIPI +183%. AGEN +42%. ABK +28%. CVM +20%. XOMA +19%. BPOP +16%. FNM +10%. KERX +8%. DCTH +7%. CROX +6%. TLB +5%. EXPE +5%. HK +5%. FRE +5%. AONE +4%.
Losers: CODI -8%. PALM -7%. MPW -4%. Comment!
Thursday, November 12, 2009, 9:00 AM Premarket gainers: COMS +33%. CAAS +17%. UBET +15%. YUII +10%. JDSU +7%. CVM +6%.
Losers: BRCD -12%. GMCR -11%. SAY -5%. ABK -4%. Comment!
Wednesday, November 11, 2009, 9:00 AM Premarket gainers: CHLN +42%. TOL +7%. ING +6%. RFMD +5%. MPEL +5%. HOV +5%. ALU +4%. MBI +4%. HL +4%. GSS +4%. ABK +4%.
Losers: HEB -14%. IRE -5%. M -4%. CVM -4%. Comment!
Monday, November 9, 2009, 9:00 AM Premarket gainers: EWBC +51%. ARIA +14%. RSH +11%. FUQI +10%. SAY +9%. TSFG +7%. NCS +7%. JASO +6%. DISH +6%. CVM +6%. AIB +6%. ANF +6%. RTP +5%. MBI +5%. NG +4%. LVS +4%. SLW +4%. HL +4%. GFI +4%. SWKS +4%. BHP +4%. FAS +4%. TGB 4%. XOMA +4%. Comment!

oldorv
$CVM,$HDSN,$LLEN, looking good long...
Apr 24, 10:42 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

wrestleout
$CVM insiders are buying CVM stock again in large numbers. I hope this means we have hit bottom 21 Cents
Mar 29, 10:32 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

holborn
$CVM today Edgar Online the board has bought 10.5 ml stocks at the price of 0.28 now, finally, they will be happy so the stocks will rise
12/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

holborn
Why all the biotech stocks up and only $CVM go down?
12/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

holborn
I am curious to know, who sell $CVM at 0.29?
12/12/12
Reply (1)

• !Report Abuse
View all 1 replies
going%20forward: buying more
12/14/12
• !Report Abuse
Add a reply...

140 characters

Droney
$CVM Does anybody know when the Phase III trial results will be released?
11/30/12
Reply (14)

• !Report Abuse
View all 14 replies
tungbh: PIII will end not later than 2016. Might get a bit early because of FDA "infant drug" priority ... or something like that.
Jan 1, 12:21 PM
• !Report Abuse
tungbh: start from 2010-12-01 till 2015-06-30 @ taiwan.
Jan 1, 12:26 PM
• !Report Abuse
Add a reply...

140 characters

Demetri Mallios
$CVM on the move today. Extremely undervalued in my opinion.
11/28/12
Reply (4)

• !Report Abuse
View all 4 replies
Droney: Thx! I will do the same.
12/5/12
• !Report Abuse
Demetri Mallios: i'm sure you've already seen this, but just in case: http://bit.ly/SIZUtY looks like they're staying pretty "tight-lipped"
12/6/12
• !Report Abuse
Add a reply...

140 characters

jmharris21
CVM - If good news today, why is the stock moving down? Still like CVM!!!
10/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

going%20forward
CVM yes more good news today
10/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy http://bit.ly/MxU9KJ $DYAX $CADX $BMRN $CYTX $CVM $AMGN $ALXN $CELG
5/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Droney
$CVM Does anybody know when the Phase III trial results will be released?
11/30/12
Reply (14)

• !Report Abuse
View all 14 replies
tungbh: PIII will end not later than 2016. Might get a bit early because of FDA "infant drug" priority ... or something like that.
Jan 1, 12:21 PM
• !Report Abuse
tungbh: start from 2010-12-01 till 2015-06-30 @ taiwan.
Jan 1, 12:26 PM
• !Report Abuse
Add a reply...

140 characters

holborn
I am curious to know, who sell $CVM at 0.29?
12/12/12
Reply (1)

• !Report Abuse
View all 1 replies
going%20forward: buying more
12/14/12
• !Report Abuse
Add a reply...

140 characters

Demetri Mallios
$CVM on the move today. Extremely undervalued in my opinion.
11/28/12
Reply (4)

• !Report Abuse
View all 4 replies
Droney: Thx! I will do the same.
12/5/12
• !Report Abuse
Demetri Mallios: i'm sure you've already seen this, but just in case: http://bit.ly/SIZUtY looks like they're staying pretty "tight-lipped"
12/6/12
• !Report Abuse
Add a reply...

140 characters

going%20forward
CVM is headed higher very soon we will have good news.
3/14/12
Reply (1)

• !Report Abuse
View all 1 replies
Noreika: I'm kicking myslef I only bought 500 shares at 0.40. Oh well.
3/21/12
• !Report Abuse
Add a reply...

140 characters

CVM Cel-Sci Corporation

CVM

Cel-Sci Corporation